TriangleHEALTH PROFESSIONAL · SOURCE READING
Adjuvant brachytherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The value of intraoperative (adjuvant) brachytherapy applied to the suture line has been evaluated in patients undergoing sublobar resections for stage I NSCLC to improve local control; it has not been found to improve outcomes.
Evidence (adjuvant brachytherapy):
A phase III trial that randomly assigned 222 patients to undergo sublobar resection with or without suture line brachytherapy reported the following:[16]
Source links and citations
A phase III trial that randomly assigned 222 patients to undergo sublobar resection with or without suture line brachytherapy reported the following:[16]
No difference in the primary end point of local recurrence (5-year estimate, 14.0% vs. 16.7%; P = .59).
A phase III trial that randomly assigned 222 patients to undergo sublobar resection with or without suture line brachytherapy reported the following:[16]
No difference in OS rates (5-year estimate, 61.4% vs. 55.6%; P = .38).[16][Level of evidence B1] vs. [Level of evidence A1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice